Replies to post #582604 on NorthWest Biotherapeutics Inc (NWBO)

[ilovetech]

Yup, but too little too late.

[vator]

With any drug approvals there is going to be for and against. I am sure there is a rebuttal by the study physicians. The folks from Brown University are not just blowing smoke up our a$$ on the efficacy they are seeing.

[flipper44]

This poor misguided author, Dr. Olivier, does not appear to understand crossover confoundment (randomization confoundment as a direct consequence), immunotherapeutic delayed impact, pseudoprogression, unprecedented long term survival and the ethical implications of denying crossover, and yet he defers to Temodar as the gold standard when it typically achieves only 3% five year survival.

He does use googly eyes on Twitter to draw attention to his journal article. Perhaps he missed his calling.

[scotty3371]

That's why shares are red!!

[HappyLibrarian]

In the DCVax-L trial, the crossover should not have been permitted. Because 90% of control patients crossed over to the experimental therapy, survival could not be reliably analyzed, in the admission of the authors themselves.

Now that was interesting as the author does not seem to buy the idea that the FDA etc. demanded NWBO have a crossover because otherwise he would be pretty foolish to criticize the trial for including a crossover when there was no choice.